Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypromellose-based nasal spray with human IgG1 anti-SARS-CoV-2 antibody for post-exposure COVID-19 prophylaxis in high-risk contacts
TCTR20220712005Phase 2Unknown
- Sponsor
- N/A
- Start
- Jun 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by N/A. Status: unknown.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220712005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220712005.